泮托拉唑及其代谢物比值作为CYP2C19表型分析新方法的评估
本研究在20名健康受试者中开展随机交叉药代动力学研究,比较泮托拉唑与奥美拉唑代谢比值对CYP2C19活性的评估能力。结果显示泮托拉唑代谢比值与 validated 探针奥美拉唑代谢比值呈强相关(Spearman ρ=0.84),且给药后4-8小时单点血浆代谢比值即可准确反映CYP2C19表型。
要点
- 泮托拉唑代谢比值与奥美拉唑代谢比值强相关(ρ=0.84),可作为CYP2C19表型替代指标。
- 给药后4-8小时单点血浆代谢比值与AUC0-8h代谢比值相关性ρ≥0.8,简化采样可行。
- 对于已服用泮托拉唑的患者,可利用其代谢比值进行CYP2C19表型分析。
核心结论
- 泮托拉唑及其代谢物4-去甲基泮托拉唑硫酸盐的代谢比值可作为CYP2C19表型分析的有效方法。
- 泮托拉唑药代动力学在重复给药时稳定,可能允许在患者使用泮托拉唑时进行CYP2C19表型分析。
研究设计与样本
- 单剂量药代动力学研究,20名健康受试者,随机交叉设计。
- 受试者分别服用10 mg奥美拉唑和20 mg泮托拉唑,洗脱期一周。
- 给药后8小时内14个时间点采血,LC-MS/MS测定药物及代谢物血浆浓度。
主要发现
- AUC0-8h代谢比值4-去甲基泮托拉唑硫酸盐/泮托拉唑与5-羟基奥美拉唑/奥美拉唑的AUC0-8h代谢比值Spearman ρ=0.84。
- 泮托拉唑给药后4-8小时单点血浆代谢比值与奥美拉唑AUC0-8h代谢比值Spearman ρ≥0.8。
关键数值与推荐
- 泮托拉唑AUC0-8h代谢比值与奥美拉唑AUC0-8h代谢比值强相关(Spearman ρ=0.84)。
- 泮托拉唑给药后4-8小时单点代谢比值与奥美拉唑AUC0-8h代谢比值显著相关(Spearman ρ≥0.8)。
临床怎么用
- 对于正在使用泮托拉唑的患者,可通过测定泮托拉唑及其代谢物血浆浓度计算代谢比值来评估CYP2C19表型。
- 采血时间可简化为给药后4-8小时单点采样,便于临床实施。
局限性
- 研究仅纳入20名健康受试者,样本量较小。
- 未在患者群体中验证,适用性需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug-drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted. The aim of this work was to validate pantoprazole as a CYP2C19 phenotyping drug. METHODS: We performed a single-dose pharmacokinetic study with 20 healthy participants in a randomized cross-over design. Participants received 10 mg omeprazole and 20 mg pantoprazole on two different study days with a washout phase of one week. Blood sampling was performed at 14 time points spanning 8 h after drug administration. Drug and metabolite plasma concentrations were assessed by LC-MS/MS. Metabolic ratios (MR) of metabolite/substrate were formed using the area under the curve from 0 to 8 h (AUC0-8h) and single plasma concentrations. RESULTS: We demonstrate very strong correlations (Spearman ρ = 0.84) of AUC0-8h MR 4-desmethylpantoprazole-sulfate/pantoprazole to the validated CYP2C19 probe AUC0-8h MR 5-hydroxyomeprazole/omeprazole (Spearman ρ = 0.84). Single time point pantoprazole MRs measured in plasma between 4 and 8 h after pantoprazole administration were sufficient for accurate CYP2C19 phenotyping by demonstrating significant and robust correlations to the AUC0-8h MR 5-hydroxyomeprazole/omeprazole with Spearman ρ ≥ 0.8. CONCLUSIONS: In contrast to omeprazole, pharmacokinetics of pantoprazole are described to be stable during repeated dosing, which may allow phenotyping of CYP2C19 with patients using pantoprazole MRs in situations where pantoprazole is part of the prescribed medication.
引用
- Müller JP, Belov VN, Yamoune S, et al. Evaluation of a pantoprazole and 4-desmethylpantoprazole-sulfate metabolic ratio as a novel CYP2C19 phenotyping method. Br J Clin Pharmacol. 2026. PMID: 42219154. doi:10.1002/bcp.70631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。